Blackstone Medical Services Partners with EnsoData to Address the 80% of Undiagnosed Sleep Apnea Cases, Improving Access and Outcomes for Patients Across the Country
Madison, WI – April 17, 2025 – Sleep apnea is a growing health concern in the United States, affecting approximately 54 million Americans, with 80% of cases remaining undiagnosed. This widespread issue continues to contribute to serious health problems, including cardiovascular disease, stroke, diabetes, and depression. As the U.S. population ages and the obesity epidemic persists, the prevalence of sleep apnea is expected to rise, increasing the number of undiagnosed cases.
In response to this challenge, Blackstone Medical Services (BMS), a Medicare-approved, JCAHO-accredited and nationally recognized IDTF for home sleep testing, partnered with EnsoData, an innovator in AI healthtech solutions, to offer improved accessibility to diagnosis and treatment for the millions of patients currently living with undiagnosed sleep apnea.
BMS leverages EnsoData’s FDA-cleared, EnsoSleep PPG home sleep testing solution to equip primary care physicians with an effective and efficient method to reach patients suffering with sleep disorders. By simplifying the identification, diagnosis, and treatment of sleep-related conditions, BMS is helping accelerate patient care, improve patient outcomes, and reduce healthcare costs.
Innovative solutions, such as the collaboration between BMS and EnsoData, overcome traditional barriers to sleep testing such as long wait times, in-person lab visits, and delayed appointments, making the process fast, effective, and patient-friendly.
“Our partnership with EnsoData allows us to provide an affordable, accessible at-home solution that is paving the way for fast, accurate diagnoses and better health outcomes nationwide,” said Vick Tipnes, Blackstone Medical CEO.
“As sleep medicine evolves, the role of accessible technology has never been more critical,” said Dr. Justin Mortara, Ph.D., EnsoData CEO, “EnsoSleep PPG provides BMS
with an avenue to reach more patients, no matter their location or ability to visit traditional sleep labs.”
Many patients face significant barriers in accessing healthcare, particularly those who live in rural or underserved areas. These patients often encounter long travel distances, limited access to sleep specialists, and prolonged wait times for sleep lab appointments. One such patient shared their experience: “My cardiologist recommended I have a sleep study because of a recent A-fib diagnosis and referred me to a sleep lab. The lab was about 45 minutes from my home and I couldn’t schedule an appointment for over 5 weeks. After expressing my concern with the length of time the lab study would take, I was referred to Blackstone. I was contacted that same day, and a device was scheduled to ship right away. I easily tested for two nights in the comfort of my own home and had results within days.”
This expanded reach not only helps improve individual patient outcomes but also contributes to reducing the gap in sleep apnea diagnosis across the country.
“We are excited about the future of sleep medicine,” Dr. Mortara added. “Continued innovation in sleep diagnostics holds the potential to change the lives of millions who are suffering due to undiagnosed sleep apnea.”
About Blackstone Medical Services: Blackstone Medical Services, is a Medicare-approved, JCAHO-accredited and nationally recognized IDTF for home sleep testing. Focused on contactless diagnostic testing, BMS is serving those suffering from Obstructive Sleep Apnea (OSA) and its services eliminate and significantly reduce hospital re-admissions and urgent care visits. Visit www.blackstonemedicalservices.com for more information.
About EnsoData: EnsoData is a healthcare technology company that uses artificial intelligence (AI) and machine learning (ML) technology to connect sleep disorder diagnosis to therapy, simplifying and accelerating the sleep care pathway for both physicians and patients. Visit www.ensodata.com/ensosleep-ppg to learn more.
